The intracranial pressure monitoring market is expected to grow from US$ US$ 1,671.41 million in 2022 and is expected to reach a value of US$ 2,433.82 million by 2028; it is anticipated to record a CAGR of 6.5% from 2023 to 2028.

The report highlights the key factors driving the intracranial pressure monitoring market growth and prominent players with their developments in the market.

Intracranial Pressure (ICP) devices measure the pressure within the cranium caused by accidents, injuries, and trauma. The ICP monitoring has post-operative and diagnostic importance in patients suffering from cranial damage caused due to stroke, hydrocephalus, or other reasons. ICP devices help surgeons save the lives of patients suffering from these injuries with the help of proper treatment and timely intervention. Generally, there are two types of ICP monitors: one provides ICP data, whereas the other is capable of concurrent cerebrospinal fluid drainage

Based on type, the intracranial pressure monitoring market is bifurcated into invasive and non-invasive. The invasive segment held the largest market share in 2022 and non-invasive is anticipated to register the highest CAGR during the forecast period. An invasive type of ICP monitoring is widely used worldwide; the widely used invasive techniques are ventriculostomy and microtransducers. Among the two techniques, ventriculostomy is considered a gold standard for accurately measuring intracranial pressure. Ventriculostomy adds an important advantage of draining CSF and administering drugs intrathecally over microtransducers. Both invasive techniques can measure ICP at various intracranial anatomical locations. Therefore, the invasive type of ICP monitoring is conventionally preferred in various healthcare facilities.

Majority of the companies which are operating in the manufacturing of neurology treatment products were working on development of treatment products for COVID- 19. For instance, in March 2020, Medtronic, one of the considerable players in the neurology treatment market, launched a new ventilator platform to assist COVID-19 patients. The research activities are expected to accelerate in the coming years owing to their potential to treat various diseases. The healthcare authorities and governments are focusing on establishing infrastructure to measure the impact of COVID-19 on neurological patients. For instance, the American Academy of Neurology (AAN) guides the care of neurology patients affected by COVID-19. The organization developed a platform to assess the impact of COVID-19 in the field of neurology overall. Pharmaceutical supplies and procurement are also badly affected by the outbreak of COVID-19 in North America.
However, the market is expected to grow in the coming years as day-to-day activities resumed by the end of 2021, post-vaccination programmes. According to 2021 statistics from the Brain Injury Research Institute, approximately 1.6 million to 3.8 million recreational and sporting concussions occur annually in the United States. Therefore, such factors contribute to the region's increasing demand for neurology diagnostic and treatment devices.

Natus Medical Inc; RAUMEDIC AG; Sophysa SA; Integra LifeSciences Holdings Corp; Medtronic Plc; Braincare Desenvolvimento e Inovacao Tecnologica SA; NovaSignal Corp; Digitimer Ltd; Longeviti Neuro Solutions LLC, and Spiegelberg GmbH & Co KG are among the leading companies operating in the global intracranial pressure monitoring market.

Companies operating in the intracranial pressure monitoring market adopt various organic and inorganic strategies. Organic strategies mainly include product launches and product approvals. Acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the intracranial pressure monitoring market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall intracranial pressure monitoring market growth. Further, acquisition and partnership strategies help them strengthen their customer base and expand their product portfolios.
A few of the significant developments by key market players are listed below.

- In April 2022, The devicemaker has agreed to be acquired by healthcare-focused private equity firm ArchiMed in a deal that would value it at about $1.2 billion and remove it from public trading. The company's board of directors has already unanimously approved the agreement and is recommending shareholders follow suit.
- In August 2022, Integra LifeSciences announced an immediate global voluntary removal of its CereLink intracranial pressure monitors after receiving reports from some customers that their readings were out of range. The Princeton, N.J.-based, medical device manufacturer is investigating the problem.
- In February 2023, NovaSignal announced donating a NovaGuide 2 intelligent ultrasound system to the Jacobs Institute in Buffalo, USA to advance stroke research and use real-time neuromonitoring to detect and help prevent intraprocedural cardiovascular and neurovascular complications in the region.